Padcev FDA Approval History
FDA Approved: Yes (First approved December 18, 2019)
Brand name: Padcev
Generic name: enfortumab vedotin-ejfv
Dosage form: for Injection
Company: Astellas and Seattle Genetics
Treatment for: Urothelial Carcinoma
Padcev (enfortumab vedotin-ejfv) is a Nectin-4 targeted antibody-drug conjugate (ADC) for the treatment of patients with locally advanced or metastatic urothelial cancer.
Development Timeline for Padcev
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.